Hereditary Nephropathy and Relatives: How Family Screening and Counseling Are Arranged

The letter arrived three weeks after her father started dialysis. It was addressed to him, but the last paragraph was about her: because his kidney failure had been traced to a change in a single gene, his adult children and his brothers were each, the nephrologist wrote, welcome to book an appointment of their own. She read it twice at the kitchen table, then rang her sister. Neither of them felt ill. Both of them had children.

That letter is how family screening for hereditary kidney disease usually starts, not with a symptom but with someone else’s diagnosis. What follows is more organized, and more optional, than most families expect. Nobody is summoned for a blood test. Instead, a counselor explains what the gene means, who in the family could carry it, what a test can and cannot say, and what would change if the answer came back positive.

This article walks through that process as it is arranged in most kidney services, from the first family tree to the follow-up plan, and separates what the evidence supports from what families often assume.

What is family screening for hereditary kidney disease, and why does it start with one person?

Clinicians call the first person diagnosed in a family the proband: the individual whose result opens the door for everyone else. Once the proband’s condition is confirmed, ideally with a specific gene change identified, the service can offer what is known as cascade screening, meaning testing that moves outward through the family tree along the lines the inheritance pattern predicts.

The logic is simple. A person with a dominant kidney condition has a 1 in 2 chance of passing it to each child (MedlinePlus Genetics), so their children and siblings sit in a higher-risk group than the general population. Testing them first, then moving to the next generation only when a parent tests positive, avoids unnecessary tests for people who cannot have inherited the gene.

Screening serves several purposes at once. It finds people whose kidneys are already affected before damage has caused symptoms, which matters because blood pressure control and avoiding kidney-toxic medicines make the most difference early (NIDDK). It also frees relatives who test negative from years of uncertainty. And it informs decisions families rarely think of in advance, such as whether a relative can safely be assessed as a living kidney donor, or how a pregnancy might be monitored.

What cascade screening is not is a compulsory program. Genetic information belongs to the person it describes, so services typically ask the proband to pass the invitation on, rather than contacting relatives directly. Some family members accept immediately. Others wait years. Both choices are respected, and the offer generally remains open.

What is the most common hereditary kidney disease?

Autosomal dominant polycystic kidney disease, usually shortened to ADPKD, is by a wide margin the most common inherited kidney disorder, affecting an estimated 1 in every 400 to 1,000 people (NIDDK). Autosomal means the responsible gene sits on one of the non-sex chromosomes, so men and women are affected equally; dominant means a single altered copy is enough to cause the disease.

In ADPKD, fluid-filled sacs called cysts grow slowly in both kidneys over decades. The kidneys can eventually enlarge to several times their normal size, crowding out working tissue. Most people have no noticeable problems in childhood; symptoms and complications typically begin between the ages of 30 and 40 (NIDDK), and NHS patient information notes that around half of people with ADPKD will need treatment for kidney failure by the age of 60.

Two genes account for most cases, PKD1 and PKD2, and which one a family carries matters for counseling, because PKD1 changes tend to produce earlier and more extensive cyst growth (MedlinePlus Genetics).

ADPKD is not the only inherited kidney condition families are screened for. Alport syndrome, a disorder of the collagen scaffolding in the kidney’s filters that also affects hearing and the eyes, occurs in about 1 in 50,000 newborns (MedlinePlus Genetics). The recessive form of polycystic kidney disease, which usually presents in infancy, affects roughly 1 in 20,000 to 40,000 people (MedlinePlus Genetics). There are also rarer tubular and cystic disorders and a growing list of single-gene causes of chronic kidney disease that were once labeled unexplained.

The reason ADPKD dominates the conversation is partly its frequency and partly its predictability: a relative’s risk can be stated clearly, and a screening test that works exists.

How inherited kidney diseases pass through a family: dominant, recessive and X-linked

The inheritance pattern determines who in a family is at risk, and therefore who is invited to screening. Three patterns cover almost every hereditary nephropathy.

Autosomal dominant. One altered gene copy is enough. Each child of an affected parent has a 50 percent chance of inheriting it, regardless of sex, and the condition typically appears in every generation (MedlinePlus Genetics). ADPKD and a minority of Alport syndrome cases follow this pattern. Screening focuses on first-degree relatives: parents, siblings and children.

Autosomal recessive. Two altered copies are needed, one from each parent. Parents are usually unaffected carriers, and each pregnancy carries a 25 percent chance of an affected child (MedlinePlus Genetics). Autosomal recessive polycystic kidney disease and about 15 percent of Alport syndrome follow this route (MedlinePlus Genetics). Here screening looks different: healthy siblings may be offered carrier testing, mainly to inform their own future family planning, while cousins and grandparents are rarely at personal risk.

X-linked. The gene sits on the X chromosome. Roughly 80 percent of Alport syndrome is X-linked (MedlinePlus Genetics). Men, who have one X chromosome, are usually more severely affected; women, who have two, range from no symptoms to significant kidney disease. An affected father passes the gene to all his daughters and none of his sons. A mother who carries it has a 50 percent chance of passing it to each child. Counselors draw this out on paper because the asymmetry surprises almost everyone.

Understanding the pattern also explains why a family can look as if a disease has skipped a generation. In X-linked and dominant conditions with variable severity, a relative may carry the gene with such mild effects that nobody ever knew.

How family screening hereditary kidney disease actually works, step by step

Most services follow a similar sequence, even if the paperwork differs.

Confirming the index diagnosis. Before relatives are approached, the team wants the proband’s diagnosis to be as precise as possible. In a family with classic ADPKD and typical imaging, the clinical diagnosis may be enough. Where the picture is unusual, or where relatives may later be tested by DNA, identifying the exact gene change in the proband comes first, because a relative’s genetic test is far more informative when the laboratory knows what it is looking for (MedlinePlus).

Drawing the pedigree. A counselor builds a three-generation family tree, recording who had kidney disease, at what age, and any linked features such as hearing loss or brain aneurysm. This map identifies which relatives are at risk and in what order testing makes sense.

Making the offer. The proband is usually given a letter or information sheet to share. Relatives who respond are booked for a counseling appointment, often before any test is arranged.

Pre-test counseling. The session covers the inheritance odds, what each test measures, the possibility of an uncertain result, and practical consequences for insurance, employment and family planning, which vary by country. Consent is documented.

Testing. Depending on the condition and the relative’s age, this may be a kidney ultrasound, a urine test for blood and protein, blood tests of kidney function, a hearing assessment, or a DNA sample, sometimes several of these.

Results and a plan. Results are given in person or by a planned call, with time to ask questions. A positive result leads to a monitoring schedule set by the nephrology team; a clear negative usually ends screening for that branch of the family.

Who is usually offered screening, and who is usually asked to wait

The strongest case for screening is an adult first-degree relative of someone with a confirmed dominant condition. A sibling or adult child of a person with ADPKD carries a 1 in 2 prior risk (MedlinePlus Genetics), and imaging can usually settle the question. These relatives are generally offered an appointment as soon as they ask for one.

Second-degree relatives, such as nieces, nephews and grandchildren, are typically approached only once the person connecting them to the proband has been tested. If that connecting relative is negative, the more distant relatives are no longer at increased risk and need no test.

Relatives in recessive families, as described above, are offered carrier testing mainly for reproductive planning rather than for their own kidney health.

Several groups are commonly asked to wait, or at least to think carefully.

• Children with no symptoms in dominant families. Because ADPKD rarely causes problems before adulthood (NHS), and because a positive result cannot be undone once known, many services defer routine screening until the young person can take part in the decision. Exceptions exist where an early result would change care, for example when childhood high blood pressure is already present.
• Relatives who are unsure they want the answer. Counseling is offered without any obligation to proceed. Some people leave the first appointment with their questions answered and no sample taken.
• People being tested for the wrong reason. A relative who wants a test only because someone else is pressing them is usually encouraged to return when the decision is their own.

Deciding who falls into which group is a clinical judgment, and it sits with the genetics and kidney teams rather than with a fixed rule.

How to test for genetic kidney disease: imaging, urine, blood and DNA

There is no single test. The right one depends on the condition, the relative’s age and what the family already knows.

Kidney ultrasound. For ADPKD in adults, ultrasound is usually the first choice. It uses sound waves, involves no radiation, and can count and measure cysts. Radiologists interpret the number of cysts against age-adjusted thresholds, because a few cysts are common in older kidneys but unusual in a young adult (NHS). In a young relative a negative scan is less reassuring, since cysts may simply not have grown large enough to see yet, which is why the result is sometimes reported as inconclusive rather than negative.

Urine tests. A dipstick and laboratory analysis look for microscopic blood and protein. For Alport syndrome, blood in the urine is often the earliest sign and may be present from childhood (MedlinePlus Genetics). For ADPKD, urine tests support the picture rather than making the diagnosis.

Blood tests. Creatinine, from which the estimated glomerular filtration rate (eGFR, a calculation of how well the kidneys filter) is derived, establishes a baseline even when it is normal, so future change can be measured (NHS).

Hearing and eye assessments. Where Alport syndrome is the concern, an audiogram and an eye examination can add supporting evidence, because the same collagen defect affects the inner ear and lens (MedlinePlus Genetics).

Genetic testing for kidney disease. A blood or saliva sample is analyzed for the gene change already found in the proband, or across a panel of kidney genes when the family variant is unknown. DNA testing is favored when imaging is inconclusive, when a relative is young, when a living-donor decision needs certainty, or when reproductive planning is the goal (MedlinePlus).

Screening tests compared: what each can and cannot tell a relative

Families often ask why one relative was sent for a scan while another gave a blood sample. The table summarizes how services usually match test to situation. Timing and thresholds are decided by the treating team and vary between conditions and countries.

Condition	Inheritance	Risk to each child of an affected parent	Usual first screen for adult relatives	Main limitation
ADPKD	Autosomal dominant	50% (MedlinePlus Genetics)	Kidney ultrasound, blood pressure, eGFR	Cysts may be too small to see in young adults; DNA test may be needed
Alport syndrome (X-linked, about 80% of cases)	X-linked	Depends on parent’s sex; 50% from a carrier mother (MedlinePlus Genetics)	Urine for blood and protein, hearing test, targeted DNA test	Women may have mild or no signs yet still carry the gene
Alport syndrome (recessive)	Autosomal recessive	25% when both parents carry (MedlinePlus Genetics)	DNA test; urine screen	Carrier parents and siblings usually have no kidney disease themselves
Autosomal recessive PKD	Autosomal recessive	25% (MedlinePlus Genetics)	Carrier DNA testing for siblings and partners	Mainly informs family planning, not personal kidney risk

Three points deserve emphasis. First, a normal ultrasound in a relative under about 40 is reassuring but not final, and the team may suggest repeating it later or adding a DNA test (NHS). Second, genetic testing is most reliable when the family’s specific variant is already known; a broad panel in a family with no identified change can return a result of uncertain significance, which is a finding nobody can yet interpret. Third, no screening test predicts how fast an individual’s disease will progress. Two siblings with the same gene change can follow quite different courses (MedlinePlus Genetics).

What genetic counseling for kidney disease actually involves

Genetic counseling is a structured conversation with a professional trained in both genetics and communication, and it is offered before and after testing (MedlinePlus). It is not a sales pitch for a test, and it is not therapy, though it borrows from both.

A first appointment usually opens with the family history. The counselor confirms who was affected and how, corrects the family tree where memories differ, and works out each person’s prior risk. From there the conversation turns to what a test would involve, how reliable it is for this family, how long results typically take in that service, and what a positive, negative or uncertain result would mean in practical terms.

Good counseling spends as much time on consequences as on biology. Would a positive result change medical care now, or only later? How might it affect life insurance or mortgage applications, which are regulated differently in different countries? Does the relative want to know before starting a family, or would they rather not? Is there anyone else, a partner or a parent, who should be part of the discussion?

The counselor also prepares people for feelings that tests provoke. Relatives who test negative sometimes describe guilt toward siblings who did not; those who test positive may grieve a future they had assumed, even while feeling relieved to have an answer. Parents frequently carry a sense of responsibility for something they could not control. Naming these reactions in advance makes them easier to manage.

After results, a second session covers the next steps: referral to nephrology for monitoring, information for other relatives, and, where relevant, reproductive options. Throughout, the counselor’s job is to inform, not to steer; the decision about testing remains with the person being tested.

Can you get PKD if your parents don't have it? Is polycystic kidney disease hereditary in every case?

Polycystic kidney disease is hereditary, but not every person with it inherited it. A minority of people with ADPKD have no affected parent because the gene change arose new, in the egg or sperm cell or very early in embryonic development. MedlinePlus Genetics describes these new, or de novo, variants as accounting for a small proportion of cases, often quoted at around 1 in 10. Once present, a new variant behaves exactly like an inherited one: the person’s own children have a 50 percent chance of receiving it.

Three other explanations make a family history look absent when it is not.

A parent was affected but never diagnosed. ADPKD, especially PKD2-related disease, can be mild enough that a parent died of something else with kidneys that were never imaged (MedlinePlus Genetics). Family stories of a grandparent with high blood pressure, or an uncle who died young of a stroke, sometimes turn out to be the trail.

The condition is recessive. In autosomal recessive PKD both parents are healthy carriers, so the disease appears to come from nowhere.

The inheritance is X-linked and passed through unaffected-seeming women. In Alport families, a mother with only microscopic blood in her urine may have no idea she carries the gene until a son is diagnosed.

For screening, the practical question is which of these applies, because it decides who else needs an offer. When a new variant is confirmed in the proband, parents and siblings are usually reassured that their own risk is not raised, while the proband’s children are still counseled as first-degree relatives. When a parent’s status is simply unknown, the team may suggest imaging or testing that parent first, since their result sorts an entire generation at once.

What the following weeks usually look like after a screening result

Results tend to send relatives down one of three paths, and each has its own rhythm.

After a positive result. Nothing dramatic happens overnight. The person is referred to a nephrology clinic, where the first visit typically establishes a baseline: blood pressure, eGFR, urine protein, and for ADPKD some measure of kidney size, since larger kidneys for age tend to predict faster decline (NIDDK). Follow-up intervals are then set by the team, commonly yearly for someone with normal kidney function and more often if function is reduced. Blood pressure is the priority, because most people with ADPKD develop hypertension and controlling it protects the kidneys and the heart (NIDDK). Relatives are usually advised to avoid non-steroidal anti-inflammatory painkillers where possible, to stay well hydrated, and to tell any prescriber about the diagnosis. Whether a specific disease-slowing medicine is appropriate is a decision for the nephrologist, made on individual measures of risk.

After a negative result. For an adult relative with a clearly negative ultrasound at an age where cysts should be visible, or a negative DNA test for a known family variant, screening ends. The person’s children are not at increased risk and need no testing (MedlinePlus Genetics). Ordinary population health advice still applies.

After an inconclusive result. This is the path families find hardest. A young adult with one or two cysts, or a variant of uncertain significance on a gene panel, is usually offered repeat imaging after an interval set by the team, a DNA test if not already done, or both. Counselors encourage people to treat this as an open question rather than a hidden diagnosis.

Across all three paths, the counselor typically checks in once more and provides written information the relative can pass along the family line.

Screening children: what changes when the relative is a minor

Whether to test a child is the question that divides families most sharply, and clinical practice reflects that tension.

Professional guidance on genetic testing in children generally favors testing when a result would change medical care during childhood, and deferring it when the benefits arrive only in adulthood (MedlinePlus). For ADPKD, which rarely causes complications before the third or fourth decade (NIDDK), many services encourage waiting until the young person can consent for themselves. A child who is labeled cannot later choose not to know, and the label may follow them into insurance and employment systems.

The counterargument is real. Some children with ADPKD develop high blood pressure early, and blood pressure is treatable. Parents may also find years of uncertainty harder than an answer. A reasonable middle ground, used in many clinics, is to monitor at-risk children with simple, non-labeling checks, blood pressure and a urine test at routine visits, without imaging or DNA testing until later.

Alport syndrome shifts the balance. Because urine abnormalities can appear in childhood and because early blood pressure management is thought to protect the kidney filters (MedlinePlus Genetics), children in Alport families are more often screened with a urine test, and referred onward if it is abnormal. Boys in X-linked families are typically prioritized because their disease course is usually more severe.

Recessive conditions raise a different issue: testing a healthy sibling tells you whether they are a carrier, which affects their future reproductive choices but not their health. Most services defer carrier testing until the sibling is old enough to decide.

Whatever is chosen, children old enough to understand are usually involved in the conversation, with language matched to their age. The decision rests with parents and the treating team together.

Relatives who want to be a living kidney donor

Few situations bring family screening into sharper focus than a sibling or adult child offering a kidney. A living donor gives up one of two kidneys and must live the rest of their life on the other, so any donor assessment includes careful evaluation of the donor’s own kidney health. In a family with an inherited condition, that evaluation must also exclude the family disease.

For ADPKD, an adult relative with a clearly normal ultrasound at an age when cysts would be expected is usually considered to have excluded the condition. Below that age, or where imaging is borderline, transplant teams commonly ask for a DNA test against the known family variant before proceeding, because a donor who unknowingly carries the gene would be left with a single kidney destined to develop cysts (NHS).

Alport families require particular care. A woman who carries an X-linked Alport variant may feel entirely well and still have a lifetime risk of kidney disease herself. Donor assessment in these families typically includes urine testing and, where possible, genetic confirmation of her status, and the transplant team weighs her own long-term risk before accepting her.

Relatives are sometimes disappointed to be turned down, and it helps to understand why: the decision protects the potential donor, not just the recipient. Being excluded as a donor does not mean a relative has been diagnosed with anything; it may simply mean uncertainty could not be resolved to the standard a transplant program requires.

Donor evaluation happens separately from family screening, with its own consent process and, in many programs, an independent advocate for the donor. Nobody is obliged to offer, and anyone who begins the process can withdraw at any point without giving a reason.

What are the symptoms of stage 3 kidney disease, and why screening does not wait for them

Chronic kidney disease is staged by the estimated glomerular filtration rate. Stage 3 covers an eGFR between 30 and 59, meaning the kidneys are filtering at roughly a third to two-thirds of normal capacity (NHS). It is a moderate reduction in function, and it is the stage at which many people are first diagnosed by chance on a routine blood test.

The uncomfortable truth is that stage 3 kidney disease usually produces no symptoms at all. The kidneys have enormous reserve, and the body compensates for a long time. When symptoms do appear they are vague and easily attributed to other things: tiredness, feeling less well than usual, swelling of the ankles, changes in how often a person passes urine (NHS). None of these is specific, and their absence says nothing about kidney function. That is exactly why family screening exists. Waiting for a relative to feel unwell means waiting until the disease has often advanced well past the point where early measures make the most difference.

In hereditary conditions, the earliest detectable changes are usually not symptoms but signs found on testing: cysts on an ultrasound, blood or protein in the urine, a blood pressure reading creeping upward. A relative with ADPKD may have a completely normal eGFR for decades while cysts are growing (NIDDK). Alport syndrome typically shows microscopic blood in the urine long before filtering capacity falls (MedlinePlus Genetics).

For a relative who has been screened and found to carry the family condition, stage 3 is a marker the nephrology team watches for, because it usually prompts closer monitoring and a more active plan for blood pressure and cardiovascular risk. For a relative who has not been screened, discovering stage 3 disease on a routine test is often the moment the family diagnosis finally surfaces.

What people often get wrong about hereditary kidney disease and family risk

“If my parent has it, I definitely have it.” In a dominant condition each child has a 50 percent chance, which means an equal chance of not having inherited it (MedlinePlus Genetics). Whole branches of families sometimes assume a diagnosis for decades and turn out to be clear.

“It skipped me, so my children are safe.” True only if you have been tested and shown not to carry the gene. Dominant conditions do not skip generations; what looks like skipping is usually an undiagnosed, mildly affected relative.

“A normal scan at 22 means I’m clear.” In ADPKD, cysts may not yet be visible in early adulthood, so a young relative’s negative ultrasound is provisional rather than final (NHS). A DNA test or a later scan may be suggested.

“Only men get Alport syndrome.” Women who carry an X-linked Alport variant can develop kidney disease, sometimes serious, and are not simply silent carriers (MedlinePlus Genetics).

“Genetic testing will tell me when I’ll need dialysis.” It will not. The gene involved gives some indication of average severity, but individual courses vary widely, even between siblings.

“There’s nothing to be done, so why find out?” Blood pressure control, avoiding kidney-toxic medicines, planning for pregnancy, and eligibility for monitoring and, where appropriate, medicines that a nephrologist may consider are all reasons a diagnosis changes care (NIDDK). Knowing also settles the question for the next generation.

“My relatives will be contacted automatically.” In most systems, the proband is asked to pass on the invitation, because confidentiality rules prevent clinicians from approaching people who are not their patients.

“Screening means a definite answer.” Sometimes it produces an uncertain one, which is frustrating but honest, and the team will say what further testing might resolve it.

Questions to ask your care team before agreeing to family screening

Counselors welcome questions, and arriving with a list tends to produce a better conversation. These are the ones that most often turn out to matter.

• Has the specific gene change in our family been identified, and if not, would finding it in the affected relative first make my own test more reliable?
• Given my age and the condition involved, which test are you suggesting for me, and how confident would a negative result be?
• If my result is uncertain, what would the next step be, and roughly how long would the team wait before repeating a scan?
• What would actually change in my medical care if I test positive, this year and in ten years?
• Who else in my family would you regard as at risk, and in what order would you suggest they be offered testing?
• How are genetic results stored, who can see them, and how might they affect insurance or employment where I live?
• If I am thinking about having children, what options exist for testing during or before a pregnancy, and who would talk me through them?
• If I have children already, what is your view on testing them now versus waiting, and what simple checks could be done in the meantime?
• Is there any reason I should be assessed or excluded as a potential living kidney donor for my relative?
• Can I have written information to share with relatives who live elsewhere, and can they be seen by a service near them?
• Is there a support organization or a patient group for this condition that the team recommends?

None of these has a single right answer; the point is to make the decision yours, informed by the team that knows your family’s specific situation.

When to call your doctor: red-flag signs for relatives with, or at risk of, hereditary kidney disease

Most of family screening happens at a measured pace, but a few situations should not wait for the next scheduled appointment. Anyone who has been diagnosed with an inherited kidney condition, or who is a first-degree relative awaiting screening, should contact their doctor promptly, or seek urgent care, if they notice the following.

• Visible blood in the urine, particularly if it is new or accompanied by pain.
• Sudden, severe pain in the side or back, especially with fever or shivering, which in ADPKD can signal an infected or bleeding cyst or a kidney stone (NIDDK).
• A sudden, severe headache unlike any experienced before, or a headache with neck stiffness, weakness, or changes in vision or speech. A minority of people with ADPKD develop brain aneurysms, and the risk is higher when another relative has had one (NIDDK); this symptom needs emergency assessment.
• Marked swelling of the legs, face or abdomen, or new breathlessness when lying flat.
• A blood pressure reading that is far above the person’s usual range, especially with headache, chest pain or confusion.
• Passing much less urine than usual, or being unable to keep fluids down because of vomiting, which can tip already-reduced kidney function into an acute decline.
• In children in Alport families, new hearing difficulty, or a school hearing test flagged as abnormal.

For anything less acute, such as a new medication being suggested by another prescriber, a planned pregnancy, or a relative asking whether they should be tested, a routine call to the kidney or genetics team is the right route. Every one of the decisions described in this article, from which test to use to whether to treat and how, rests with the clinicians who know the individual and the family; this explainer is meant to help you ask them better questions, not to replace them.

Frequently asked questions

What is the most common hereditary kidney disease?

Autosomal dominant polycystic kidney disease, or ADPKD, is the most common inherited kidney disorder, affecting an estimated 1 in every 400 to 1,000 people according to NIDDK. Fluid-filled cysts grow slowly in both kidneys over decades, and problems typically appear between ages 30 and 40. Because a single altered gene copy causes it, each child of an affected parent has a 50 percent chance of inheriting the condition, which makes structured family screening especially useful.

How do you test for genetic kidney disease in a relative?

The test depends on the condition and the relative’s age. For ADPKD in adults, a kidney ultrasound counting cysts against age-adjusted thresholds is usually first. For Alport syndrome, urine testing for blood and protein plus a hearing check is common. Genetic testing for kidney disease, using a blood or saliva sample, is favored when imaging is inconclusive, when the relative is young, or when the family’s exact gene change is already known and can be looked for directly.

Can you get PKD if your parents don't have it?

Yes. A minority of people with ADPKD have a new gene change that arose spontaneously, often quoted at around 1 in 10 cases in MedlinePlus Genetics. Others have a parent who was affected mildly and never diagnosed, or a recessive form in which both parents are healthy carriers. Whatever the origin, once the gene change is present the person’s own children face a 50 percent chance of inheriting it in the dominant form.

What are the symptoms of stage 3 kidney disease?

Stage 3 kidney disease, an eGFR between 30 and 59, usually causes no symptoms at all; most people are diagnosed on a routine blood test. When symptoms occur they are non-specific, such as tiredness, ankle swelling or changes in urination, and their absence does not mean the kidneys are healthy. This is why relatives in families with hereditary kidney disease are screened with scans, urine and blood tests rather than waiting to feel unwell.

Is polycystic kidney disease hereditary in every case?

Polycystic kidney disease is a genetic condition, but not every case is inherited from a parent. Most people with ADPKD have an affected parent, while a small proportion carry a new gene change. The rarer recessive form requires an altered gene from both parents, who are usually unaffected carriers. In all forms the condition is passed on genetically from that point, which is why counseling addresses children’s risk even when no earlier family history exists.

How does Alport syndrome inheritance affect who gets screened?

Roughly 80 percent of Alport syndrome is X-linked, according to MedlinePlus Genetics. An affected father passes the gene to all daughters and no sons; a carrier mother has a 50 percent chance of passing it to each child. Men are usually more severely affected, but women can develop kidney disease too. Screening therefore prioritizes sons of carrier mothers and daughters of affected fathers, typically with urine tests, hearing checks and, where possible, a targeted DNA test.

What does genetic counseling for kidney disease cover?

Genetic counseling is a structured conversation before and after testing. The counselor builds a family tree, explains each relative’s risk, describes what a test can and cannot show, and discusses consequences for insurance, employment and family planning, which vary by country. It also prepares people for the emotional impact of results and, afterward, explains referral for monitoring and how to inform other relatives. The decision to test always remains with the person being counseled.

Should children be screened for polycystic kidney disease?

Practice varies, and many services suggest waiting. Because ADPKD rarely causes complications before adulthood, and a positive result cannot be unlearned, clinicians often defer imaging or DNA testing until the young person can consent. In the meantime, simple checks such as blood pressure and urine testing at routine visits can be used. Alport families are treated differently, since urine changes can appear in childhood. The choice rests with parents and the treating team together.

Can a relative with ADPKD in the family donate a kidney?

Sometimes, but only after the family condition has been excluded in the potential donor. An adult with a clearly normal ultrasound at an age when cysts would be visible is usually considered clear; younger relatives or those with borderline scans are typically asked to have a DNA test against the known family variant. Being turned down protects the donor, who must live on a single kidney, and does not itself mean a diagnosis has been made.

What happens if my genetic test result is uncertain?

An uncertain result, such as a variant of unknown significance or a young adult’s scan with only one or two cysts, means the question is open rather than answered. The team usually offers repeat imaging after an interval they set, a DNA test if not already done, or both. Counselors encourage people to avoid treating uncertainty as a hidden diagnosis, and to keep routine checks of blood pressure and urine while waiting.

References

• MedlinePlus Genetics: Polycystic kidney disease
• MedlinePlus Genetics: Alport syndrome
• NHS: Autosomal dominant polycystic kidney disease (ADPKD)
• NIH NIDDK: Autosomal Dominant Polycystic Kidney Disease

This article is for general information only and is not a substitute for professional medical advice. Please consult a qualified doctor about your individual situation.